FHTX
NASDAQ HealthcareFoghorn Therapeutics Inc. - Common Stock
Biotechnology
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
�� 市场数据
| 价格 | $5.29 |
|---|---|
| 成交量 | 153,164 |
| 市值 | 310.52M |
| 贝塔系数 | 3.110 |
| RSI（14日） | 71.6 超买 |
| 200日均线 | $5.09 |
| 50日均线 | $5.22 |
| 52周最高 | $6.95 |
| 52周最低 | $3.27 |
| Forward P/E | -5.80 |
| Price / Book | -2.76 |
🎯 投资策略评分
FHTX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (98/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 FHTX in your text
粘贴任何文章、记录或帖子 — 工具将提取 FHTX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.